98%
921
2 minutes
20
The lipid phosphatase Ship2 interacts with the EphA2 receptor by forming a heterotypic Sam (sterile alpha motif)-Sam complex. Ship2 works as a negative regulator of receptor endocytosis and consequent degradation, and anti-oncogenic effects in cancer cells should be induced by hindering its association with EphA2. Herein, a computational approach is presented to investigate the relationship between Ship2-Sam/EphA2-Sam interaction and cancer onset and further progression. A search was first conducted through the COSMIC (Catalogue of Somatic Mutations in Cancer) database to identify cancer-related missense mutations positioned inside or close to the EphA2-Sam and Ship2-Sam reciprocal binding interfaces. Next, potential differences in the chemical-physical properties of mutant and wild-type Sam domains were evaluated by bioinformatics tools based on analyses of primary sequences. Three-dimensional (3D) structural models of mutated EphA2-Sam and Ship2-Sam domains were built as well and deeply analysed with diverse computational instruments, including molecular dynamics, to classify potentially stabilizing and destabilizing mutations. In the end, the influence of mutations on the EphA2-Sam/Ship2-Sam interaction was studied through docking techniques. This in silico approach contributes to understanding, at the molecular level, the mutation/cancer relationship by predicting if amino acid substitutions could modulate EphA2 receptor endocytosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10935306 | PMC |
http://dx.doi.org/10.3390/molecules29051024 | DOI Listing |
Cancers (Basel)
August 2025
Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37235, USA.
Background: EphA2 is a receptor tyrosine kinase that contributes to tumor growth and metastasis and has been identified as a viable target for many solid cancers. Investigating EphA2's impact on the host immune system may advance our understanding of tumor immune evasion and the consequences of targeting EphA2 on the tumor microenvironment.
Methods: Here, we examine how tumor-specific EphA2 affects the activation and infiltration of immune cell populations and the cytokine and chemokine milieu in murine models of non-small cell lung cancer (NSCLC).
Biophys J
August 2025
Department of Mathematics, University of Tennessee, Knoxville, TN. Electronic address:
With the growing adoption of single-molecule fluorescence experiments, there is an increasing demand for efficient statistical methodologies and accurate analysis of the acquired measurements. Existing analysis frameworks, such as those that use kinetic models, often rely on strong assumptions on the dynamics of the molecules and fluorophores under study that render them inappropriate for general purpose step counting applications, especially when the systems of study exhibit uncharacterized dynamics. Here, we propose a novel Bayesian nonparametric framework to analyze single-molecule fluorescence data that is kinetic model independent.
View Article and Find Full Text PDFCell Cycle
September 2025
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Colorectal cancer (CRC) remains a significant global health concern, and reliable biomarkers are needed to improve early diagnosis, prognostication, and personalized treatment strategies. This study investigated the expression of cell surface proteins and serum exosomal miRNAs in CRC patients. Tissue microarrays (TMAs) constructed from primary and metastatic CRC samples were analyzed for five cell surface proteins: EphB1, EphB3, EphA2, cMet, and EphB4.
View Article and Find Full Text PDFACS Appl Mater Interfaces
August 2025
CAS Center for Excellence in Nanoscience, Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
The majority of lysosome-targeting degradation strategies for membrane proteins rely on recruiting specific lysosome-targeting receptors; however, the low expression levels of these receptors in tumor cells limit their further applications. Herein, we design covalent membrane protein aggregate-targeting chimeras, termed CMPATACs, for tumor-specific membrane protein degradation, which do not rely on specific receptors. We first utilized a covalent reaction to irreversibly bind specific membrane proteins, and this process facilitates the formation of membrane protein aggregates that enter the lysosome for degradation, leading to improved anticancer capacity.
View Article and Find Full Text PDFbioRxiv
August 2025
Division of Cancer Biology, Department of Medicine, MetroHealth Center for Cancer Research, MetroHealth Campus, Case Western Reserve University, Cleveland, OH, United States.
The 14 members of Eph receptor tyrosine kinases (RTK) bind to membrane-tethered ligand called ephrins and mediate cell contact signaling where the receptors and ligands engage on adjacent cells. Previous studies reveal that some Eph and ephrin pairs are coexpressed on the same cells, including EphA3-ephrin-A3 and EphA4/ephrin-A5, can also interact with each other . However, significant discrepancies persist as to the molecular basis and functional significance of the interactions, owning to the difficulties to directly interrogate the interactions.
View Article and Find Full Text PDF